Towards effective immunotherapy for lung cancer: Simultaneous targeting of tumor-initiating cells and immune pathways in the tumor microenvironment

Immunotherapy

Volumn 1, Issue 5, 2009, Pages 721-725

  Dubinett, Steven ^a,b   Sharma, Sherven ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 23; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TRANSFORMING GROWTH FACTOR BETA; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTATION; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER STEM CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CROSS PRESENTATION; DENDRITIC CELL; EDITORIAL; HUMAN; IMMUNOLOGICAL TOLERANCE; LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TARGET CELL DESTRUCTION; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; ANTIGEN PRESENTATION; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; LUNG NEOPLASMS; MYELOID PROGENITOR CELLS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 77953461432     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/IMT.09.56     Document Type: Editorial

References (61)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J. Clin. 55(2), 74-108 (2005).
2. Chouaib S, Assellin-Paturel C, Mami-Chouaib F, Caignard A, Blay J: The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol. Today 18, 493-497 (1997). (Pubitemid 27441593)
3. Smyth MJ, Trapani JA: Lymphocyte-mediated immunosurveillance of epithelial cancers? Trends Immunol. 22(8), 409-411 (2001).
4. Huang M, Stolina M, Sharma S et al.: Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res. 58(6), 1208-1216 (1998). (Pubitemid 28183210)
5. Huang M, Sharma S, Mao JT, Dubinett SM: Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J Immunol. 157, 5512-5520 (1996). (Pubitemid 126448972)
6. Alleva DG, Burger CJ, Elgert KD: Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-α production: role of tumor-derived IL-10, TGF-β and prostaglandin E2. J. Immunol. 153, 1674 (1994).
7. Halak BK, Maguire HC Jr, Lattime EC: Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res. 59(4), 911-917 (1999).
8. Maeda A, Hiyama K, Yamakido H, Ishioka S, Yamakido M: Increased expression of platelet-derived growth factor A and insulin-like growth factor-1 in BAL cells during the development of bleomycin-induced pulmonary fibrosis in mice. Chest 109, 780-786 (1996). (Pubitemid 26086949)
9. Coussens LM, Werb Z: Inflammation and cancer. Nature 420(6917), 860-867 (2002). • Important review of articles on the concept that inflammation is important for tumor progression. Certain inflammatory cells contribute in the neoplastic process by supporting tumor proliferation, survival and migration.
10. Peebles KA, Lee JM, Mao JT et al.: Inflammation and lung carcinogenesis: applying findings in prevention and treatment. Expert Rev. Anticancer Ther. 7(10), 1405-1421 (2007).
11. Andersson A, Yang SC, Huang M et al.: IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J. Immunol. 182(11), 6951-6958 (2009). • Demonstrates how γc homeostatic cytokine IL-7 restores T cell activity and can be used in combined immune based strategies against lung cancer.
12. Huang AYC, Golumbek P, Ahmadzadeh M et al.: Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264, 961-965 (1994). • Defined the importance of host antigen-presenting cells in tumor antigen presentation. (Pubitemid 2099147)
13. Moretta A, Bottino C, Vitale M et al.: Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 19, 197-223 (2001). (Pubitemid 32368034)
14. Smyth MJ, Crowe NY, Hayakawa Y et al.: NKT cells - conductors of tumor immunity? Curr. Opin. Immunol. 14(2), 165-171 (2002). (Pubitemid 34188474)
15. + T cells: when, where, and how. Annu. Rev. Immunol. 24, 519-540 (2006).
16. Belardelli F, Ferrantini M: Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol. 23(4), 201-208 (2002). (Pubitemid 34260936)
17. Restifo NP, Esquivel F, Kawakami Y et al.: Identification of human cancers deficient in antigen processing. J. Exp. Med. 177, 265-272 (1993). (Pubitemid 23117076)
18. Albert ML, Sauter B, Bhardwaj N: Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392(6671), 86-89 (1998). (Pubitemid 28150594)
19. Bevan MJ: Antigen presentation to cytotoxic T lymphocytes in vivo. J. Exp. Med. 182, 639-641 (1995).
20. Staveley-O'Carroll K, Sotomayor E, Montgomery J et al.: Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl Acad. Sci. USA 95(3), 1178-1183 (1998). (Pubitemid 28124932)
21. Cuenca A, Cheng F, Wang H: Extralymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res. 63(24), 9007-9015 (2003). (Pubitemid 38064082)
22. Willimsky G, Blankenstein T: Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437(7055), 141-146 (2005). (Pubitemid 41613441)
23. Sotomayor EM, Borrello I, Rattis FM: Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood 98(4), 1070-1077 (2001).
24. Steinman RM, Hawiger D, Nussenzweig MC: Tolerogenic dendritic cells. Annu. Rev. Immunol. 21, 685-711 (2003).
25. + dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J. Exp. Med. 196(8), 1099-1104 (2002).
26. Munn DH, Sharma MD, Lee JR et al.: Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297(5588), 1867-1870 (2002).
27. Fuchs EJ, Matzinger P: Is cancer dangerous to the immune system? Semin. Immunol. 8(5), 271-280 (1996).
28. Gerlini G, Tun-Kyi A, Dudli C: Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions. Am. J. Pathol. 165(6), 1853-1863 (2004).
29. Gabrilovich DI, Chen HL, Girgis KR et al.: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2(10), 1096-1103 (1996).
30. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S: Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immunol. 20, 621-667 (2002). (Pubitemid 34293436)
31. Dieu-Nosjean MC, Antoine M, Danel C et al.: Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J. Clin. Oncol. 26(27), 4410-4417 (2008).
32. Sharma S, Stolina M, Yang SC et al.: Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin. Cancer Res. 9(3), 961-968 (2003). (Pubitemid 36323698)
33. Woo EY, Yeh H, Chu CS et al.: Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 168(9), 4272-4276 (2002). (Pubitemid 34441324)
34. Sakaguchi S: Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101(5), 455-458 (2000).
35. Boon T, Cerottini J-C, Van den Eynde B, van der Bruggen P, Van Pel A: Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12, 337-365 (1994).
36. + regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J. Immunother. 25(3), 207-217 (2002). • Demonstrates that depleting T-regulatory cells aid in the generation of specific antitumor T-cell responses. (Pubitemid 34533310)
37. Dannull J, Su Z, Rizzieri D et al.: Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115(12), 3623-3633 (2005). (Pubitemid 43121851)
38. + T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163(10), 5211-5218 (1999).
39. Onizuka S, Tawara I, Shimizu J et al.: Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res. 59(13), 3128-3133 (1999). (Pubitemid 29316012)
40. + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194(6), 823-832 (2001).
41. + regulatory T cell suppression of dendritic cell function involves TGF-β and IL-10. Cancer Immunol. Immunother. 56(1), 48-59 (2007). (Pubitemid 44812446)
42. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl Acad. Sci. USA 102(51), 18538-18543 (2005). (Pubitemid 43011261)
43. Alvaro T, Lejeune M, Salvado MT et al.: Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J. Clin. Oncol. 24(34), 5350-5357 (2006). (Pubitemid 46623165)
44. Galon J, Costes A, Sanchez-Cabo F et al.: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795), 1960-1964 (2006).
45. Gao Q, Qiu SJ, Fan J et al.: Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J. Clin. Oncol. 25(18), 2586-2593 (2007). (Pubitemid 47041232)
46. + cells within human head and neck squamous cell carcinomas. J. Immunol. 159(2), 990-996 (1997).
47. Kusmartsev SA, Kusmartseva IN, Afanasyev SG, Cherdyntseva NV: Immunosuppressive cells in bone marrow of patients with stomach cancer. Adv. Exp. Med. Biol. 451, 189-194 (1998).
48. Young MR, Newby M, Wepsic HT: Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors. Cancer Res. 47(1), 100-105 (1987). (Pubitemid 17002105)
49. Subiza JL, Vinuela JE, Rodriguez R, Gil J, Figueredo MA, De La Concha EG: Development of splenic natural suppressor (NS) cells in Ehrlich tumor-bearing mice. Int. J. Cancer 44(2), 307-314 (1989). (Pubitemid 19217219)
50. Kusmartsev SA, Ogreba VI: Suppressor activity of bone marrow and spleen cells in C57Bl/6 mice during carcinogenesis induced by 7,12-dimethylbenz(a) anthracene. Eksp. Onkol. 11(5), 23-26 (1989).
51. Gabrilovich DI, Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9(3), 162-174 (2009). • Informative review on the immune suppressive role of myeloid-derived suppressor cells in cancer.
52. Schmidt-Wolf IG, Dejbakhsh-Jones S, Ginzton N, Greenberg P, Strober S: T-cell subsets and suppressor cells in human bone marrow. Blood 80(12), 3242-3250 (1992). (Pubitemid 23004530)
53. Young MR, Wright MA, Matthews JP, Malik I, Prechel M: Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-β and nitric oxide. J. Immunol. 156(5), 1916-1922 (1996).
54. Sugiura K, Inaba M, Ogata H et al.: Wheat germ agglutinin-positive cells in a stem cell-enriched fraction of mouse bone marrow have potent natural suppressor activity. Proc. Natl Acad. Sci. USA 85(13), 4824-4826 (1988).
55. Angulo I, Rodriguez R, Garcia B et al.: Involvement of nitric oxide in bone marrow-derived natural suppressor activity. Its dependence on IFN-γ. J. Immunol. 155(1), 15-26 (1995).
56. + natural suppressor cells on IL-2 and IL-4 utilization in MLR. Transplantation 58(10), 1096-1103 (1994).
57. Talmadge JE: Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res. 13(18 Pt 1), 5243-5248 (2007).
58. Sica A, Larghi P, Mancino A et al.: Macrophage polarization in tumour progression. Semin. Cancer Biol. 18(5), 349-355 Epub 2008 Mar 2026 (2008).
59. Condeelis J, Pollard JW: Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124(2), 263-266 (2006). (Pubitemid 43121975)
60. Allavena P, Sica A, Solinas G, Porta C, Mantovani A: The inflammatory microenvironment in tumor progression: the role of tumor-associated macrophages. Crit. Rev. Oncol. Hematol. 66(1), 1-9 (2008). (Pubitemid 351324128)
61. Lewis CE, Pollard JW: Distinct role of macrophages in different tumor microenvironments. Cancer Res. 66(2), 605-612 (2006).